Skip to main content

Table 1 Immunohistochemical results of MMP-9, VEGF and PCNA

From: Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma

  Group N Expression density No of cases % P
MMP-9 I 15     
    ++ 13 86.67 < 0.01
    + 2 13.33  
    - 0 0.00  
  II 15     
    ++ 5 33.33  
    + 9 60.00  
    - 1 6.67  
  III 15     
    ++ 4 26.67  
    + 10 66.67  
    - 1 6.67  
  Control 15     
    ++ 0 0.00  
    + 7 46.67  
    - 8 53.33  
VEGF I 15     
    ++ 12 80.00 < 0.01
    + 3 20.00  
    - 0 0.00  
  II 15     
    ++ 5 33.33  
    + 9 60.00  
    - 1 6.67  
  III 15     
    ++ 3 20.00  
    + 10 66.67  
    - 2 13.33  
  Control 15     
    ++ 0 0.00  
    + 6 40.00  
    - 9 60.00  
PCNA I 15     
    ++ 11 73.33 < 0.01
    + 4 26.67  
    - 0 0.00  
  II 15     
    ++ 4 26.67  
    + 10 66.67  
    - 1 6.67  
  III 15     
    ++ 2 13.33  
    + 12 80.00  
    - 1 6.67  
  Control 15     
    ++ 0 0.00  
    + 5 33.33  
    - 10 66.67  
  1. MMP-9: matrix metalloproteinase 9; VEGF: vascular endothelial growth factor; PCNA: proliferating cell nuclear antigen. Any slides that exhibited diffuse immunostaining or > 50% tumor cells were classified as (++), > 10% but < 50% as (+), and < 10% as (-). (P < 0.01, by Kruskal-Wallis H test)